10,480 Shares in Edwards Lifesciences Corporation $EW Bought by WoodTrust Financial Corp

WoodTrust Financial Corp bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 3rd quarter, HoldingsChannel reports. The firm bought 10,480 shares of the medical research company’s stock, valued at approximately $904,000.

Several other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $5,318,092,000. Varma Mutual Pension Insurance Co bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $11,168,000. Conway Capital Management Inc. bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth $954,000. Commerce Bank purchased a new position in Edwards Lifesciences in the second quarter worth $3,121,000. Finally, Bank of America Corp DE purchased a new position in Edwards Lifesciences in the second quarter worth $605,397,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel Lippis sold 619 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 544 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the transaction, the senior vice president owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 5,045 shares of company stock valued at $451,596 in the last ninety days. Company insiders own 0.31% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. Mizuho boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Trading Down 0.4%

Shares of NYSE:EW traded down $0.33 on Friday, reaching $83.91. 1,555,942 shares of the company traded hands, compared to its average volume of 4,508,433. The stock has a market capitalization of $48.31 billion, a P/E ratio of 48.13, a price-to-earnings-growth ratio of 2.25 and a beta of 0.87. The business’s 50-day simple moving average is $88.74 and its 200 day simple moving average is $86.17. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.Edwards Lifesciences’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation is a medical technology company focused on therapies for structural heart disease and other cardiovascular conditions. The company develops and manufactures heart valve replacement and repair technologies, including transcatheter aortic valve replacement systems, surgical heart valves, transcatheter mitral and tricuspid therapies, and related delivery systems and accessories.

Founded in 1958 by engineer Miles “Lowell” Edwards, the company helped pioneer artificial heart valves and has played a significant role in the development of transcatheter valve replacement.